Profile


A Phase IV, Prospective, Single-Arm, Open-Label Study to measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
02/25/2015 - 02/24/2020 (PI)
Bayer HealthCare Pharmaceuticals


A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo Controlled Study of GS-4997 in subjects with Pulmonary Arterial Hypertension
12/22/2014 - 12/21/2019 (PI)
Gilead Sciences, Inc.


A 24-Week Pilot Study to Investigate Changes in Proteomic and Genomic Profiles in Patients with Pulmonary Arterial Hypertension Associated with Scleroderma Treated with Macitentan-PIONEER 2
11/05/2015 - 11/04/2019 (PI)
Actelion Pharmaceuticals, Ltd.


REPAIR: Right Ventricular Remodeling in Pulmonary Arterial Hypertension
07/15/2015 - 07/14/2019 (PI)
Actelion Pharmaceuticals, Ltd.


Uptravi® (SelexiPag): tHe usErs dRug rEgistry
09/01/2016 - 08/31/2018 (PI)
Actelion Pharmaceuticals US, Inc.


A Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca
06/11/2014 - 06/06/2018 (PI)
Actelion Clinical Operations, Inc.


A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Sympto
06/01/2012 - 05/31/2017 (PI)
Ikaria


A multi-Center, Double Blind, Placebo-Controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients with Pulmonary Hypertension
04/01/2011 - 05/31/2017 (PI)
Actelion Pharmaceuticals, Ltd.


EPOCH Treatment Satisfaction Qualitative Study (EPOCH-TSQS)
03/10/2015 - 03/09/2017 (PI)
Actelion Pharmaceuticals, Ltd.


A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument
10/17/2013 - 01/01/2017 (PI)
Actelion Pharmaceuticals, Ltd.


Showing 10 of 41 results. Show All Results



Yr Title Project-Sub Proj Pubs
2017 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 1R21AR069285-01A1
2015 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-05-7133 25
2014 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-04-7133 25
2013 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-03-7133 25
2012 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-02-7133 25
2011 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 1P50AR060780-01-7133 25
2007 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-05-2 78
2006 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-04 1
2006 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-04-2 78
2005 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-03 1
Showing 10 of 25 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR. Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm. N Engl J Med. 2018 Apr 12; 378(15):1430-1438. PMID: 29641962.
     
  2. Farber HW, Benza RL. Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials? Am J Respir Crit Care Med. 2018 Apr 01; 197(7):843-845. PMID: 29373796.
     
  3. Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 Aug; 37(8):948-955. PMID: 29653800.
     
  4. Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018 Jul; 37(7):836-843. PMID: 29580746.
     
  5. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 Jul; 154(1):126-135. PMID: 29355551.
     
  6. Abston E, Farber H. Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. Open Forum Infect Dis. 2018 Feb; 5(2):ofy023. PMID: 29450215.
     
  7. Miller DP, Farber HW. Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party). Circulation. 2017 Nov 21; 136(21):2034-2036. PMID: 29158214.
     
  8. Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2018 Apr; 37(4):513-519. PMID: 29223470.
     
  9. Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun; 37(6):696-705. PMID: 29174533.
     
  10. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 Mar; 37(3):401-408. PMID: 29096938.
     
Showing 10 of 209 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 24 publications over 16 distinct years, with a maximum of 3 publications in 1993 and 2003

YearPublications
19872
19901
19911
19921
19933
19951
19962
19972
20001
20033
20051
20061
20071
20082
20091
20121
Contact for Mentoring: